Fig. 2: Ursodeoxycholic acid does not influence the cisplatin sensitivity of A2780 cells. | Cell Death Discovery

Fig. 2: Ursodeoxycholic acid does not influence the cisplatin sensitivity of A2780 cells.

From: Ursodeoxycholic acid prompts glycolytic dominance, reductive stress and epithelial-to-mesenchymal transition in ovarian cancer cells through NRF2 activation

Fig. 2

A–C A2780 cells were plated in 96 well plates (104 cells/well for the MTT assay for both cell lines; for SRB 2 × 103 cisplatin sensitive cells/well and 6 × 103 cisplatin resistant cells/well) and were treated with cisplatin as indicated with or without 300 nM UDCA. In the MTT assay (A) the treatment lasted 4 h, in the SRB assay (B) the treatment lasted 48 h. The IC50 values obtained from the SRB assay are depicted on (C). Data are presented as means ± SD. Except for the SRB assay on cisplatin-sensitive cells, where 5 biological replicates are presented, all other assays were performed in 3 biological replicates. Individual assays were measured in duplicates. Values were normalized to vehicle-treated cells (absorbance is equal to 1). Nonlinear regression (GraphPad “[Inhibitor] vs. response (four parameters)” utility) was performed on datasets to obtain IC50 values. Normality of the IC50 values were determined using the Shapiro-Wilk test. Statistical difference between the inhibitory curves was performed non-paired, two-sided t-test was applied. CisPt cisplatin, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, SRB sulforhodamine B, UDCA ursodeoxycholic acid.

Back to article page